We demonstrate that the enhancement of proteasome inhibitors induced by apoptosis by Parkin in HCC is not observed in the normal hepatic cells, supporting that targeting Parkin is a safe and effective anticancer strategy for HCC. This evidence concerns the gene PRKN and hepatocellular carcinoma.